Pfizer Corporation

Peter J Oates

Banavara L Mylari

William J Zembrowski

Delvin R Knight, Jr

W Ross Tracey

Todd W Siegel

Thomas A Beyer

E Roy Pettipher

A method of preventing non-cardiac tissue damage resulting from ischemia, comprising administering to a patient in need of such treatment an effective amount of an aldose reductase inhibitor.

Method of reducing tissue damage associated with non-cardiac ischemia

A method of preventing tissue damage resulting from ischemia, comprising administering to a patient in need of such treatment an effective amount of a sorbitol dehydrogenase inhibitor.

Method of reducing tissue damage associated with ischemia

This invention relates to methods of inhibiting sorbitol dehydrogenase, lowering fructose levels, and treating or preventing diabetic complications such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, diabetic microangiopathy or diabetic macroangiopathy in a mammal using pyrimidine derivatives of the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are defined as below, and to pharmaceutical compositions containing such derivatives. It also relates to certain novel substituted pyrimidines having the above formula. It also relates to mutual prodrugs of compounds of the formula I and aldose reductase inhibiting compounds, and to pharmaceutical compositions comprising a compound of the formula I and an aldose reductase inhibitor.

Substituted pyrimidines for control of diabetic complications

Substituted pyridmidines for control of diabetic complications

Growing community of inventors

Gales Ferry, CT, United States of America

Peter J Oates